STATE PATENT AND TRADE **COPY OF PAPERS**

Application No.:

tba

Filed:

tba

1st Inventor:

H. ODAKA

For:

Pharmaceutical Composition For The

Treatment of Diabetes

Atty. Dkt. No.

2530 US1P

Art Unit:

Examiner:

Allowed:

Batch:

Paper No.:



Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231 Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference has been previously submitted to the Patent Office in prior patent application Serial No. 09/380,059.

This information disclosure statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: October 29, 2001

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA

Page 1 of FORM PTO 144	19 (mod.	ified)			Y DOCKET NO	D.:	SERIAL NO.:		
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:					2530USLP APPLICANT: ODAKA Hiroyuki and YAMANE Masahiro				
					FILING DATE:		GROUP:		
					NT DOCUMEN			T not to a not	n .n
*EXAMINER INITIAL	REF No.	DOCUMENT DATE NUMBER			NAME	CLAS	SUBCLASS	CLASS FILING DATE IF APPROPRIATE	
	_								
	!		FOREIG	N PA1	TENT DOCUM	ENTS		<u> </u>	
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE		COUNTRY	CLAS	SUBCLASS	SUBCLASS TRANSLATI YES N	
	A1	EP 0749751-X	Dec. 27, '9						
	A2	EP 0516349-A	Dec. 2, '92						
	A3	WO 93/03724	Mar. 4, '9						
	A4	WO 97/27847	Aug. 7, '9'			-			
<u> </u>									1
							_		
	-								
	A5	OTHER DOCUM	MENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.) A. Okuno et al., "Effects of Thiazolidine Derivatives on Zucker Fatty Rat Adipose Tissue" Diabetes Frontier Vol. 8, 1997 pp. 499-501 (With its English translation)						
	A6	A.A. Kheir El-Din et al., "Possible Interactions of Some Anorexigenic Drugs" Egypt J. Pharm. Sci. Vol. 29, No. 1-4, pp.355-366 (1988)							
EXAMINER:					OATE CONSID				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.